COVID-19: Present and Future Challenges for Dental Practice

Najla-Dar Odeh, Hamzah Babkair, Shaden Abu-Hammad, Sary Borzangy, Abdalla Abu-Hammad, Osama Abu-Hammad, Najla-Dar Odeh, Hamzah Babkair, Shaden Abu-Hammad, Sary Borzangy, Abdalla Abu-Hammad, Osama Abu-Hammad

Abstract

COVID-19 was declared a pandemic by the World Health Organization, with a high fatality rate that may reach 8%. The disease is caused by SARS-CoV-2 which is one of the coronaviruses. Realizing the severity of outcomes associated with this disease and its high rate of transmission, dentists were instructed by regulatory authorities, such as the American Dental Association, to stop providing treatment to dental patients except those who have emergency complaints. This was mainly for protection of dental healthcare personnel, their families, contacts, and their patients from the transmission of virus, and also to preserve the much-needed supplies of personal protective equipment (PPE). Dentists at all times should competently follow cross-infection control protocols, but particularly during this critical time, they should do their best to decide on the emergency cases that are indicated for dental treatment. Dentists should also be updated on how this pandemic is related to their profession in order to be well oriented and prepared. This overview will address several issues concerned with the COVID-19 pandemic that directly relate to dental practice in terms of prevention, treatment, and orofacial clinical manifestations.

Keywords: COVID-19; aerosol; dentistry; manifestations; oral; saliva.

Conflict of interest statement

Authors declare that they have no conflict of interest.

References

    1. Amariles P., Granados J., Ceballos M., Montoya C.J. COVID-19 in Colombia endpoints. Are we different, like Europe? Res. Soc. Adm. Pharm. 2020 doi: 10.1016/j.sapharm.2020.03.013. in press.
    1. Brown J.D. Antihypertensive drugs and risk of COVID-19? Lancet Respir. Med. 2020 doi: 10.1016/S2213-2600(20)30158-2.
    1. Day M. Covid-19: Four fifths of cases are asymptomatic, China figures indicate. BMJ. 2020;369:m1375. doi: 10.1136/bmj.m1375.
    1. Du Y., Tu L., Zhu P., Mu M., Wang R., Yang P., Wang X., Hu C., Ping R., Hu P., et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study. Am. J. Respir. Crit. Care Med. 2020 doi: 10.1164/rccm.202003-0543OC.
    1. World Health Organization (WHO) Personal Protective Equipment. [(accessed on 27 April 2020)]. Available online:
    1. American Dental Association ADA Coronavirus (COVID-19) Center for Dentists. [(accessed on 27 April 2020)]. Available online:
    1. American Dental Association What Constitutes a Dental Emergency? [(accessed on 27 April 2020)]. Available online: .
    1. Dar-Odeh N., Fadel H.T., Abu-Hammad S., Abdeljawad R., Abu-Hammad O.A. Antibiotic prescribing for Oro-facial infections in the paediatric outpatient: A review. Antibiotics. 2018;7:38. doi: 10.3390/antibiotics7020038.
    1. Durkin M.J., Hsueh K., Sallah Y.H., Feng Q., Jafarzadeh S.R., Munshi K.D., Lockhart P.B., Thornhill M.H., Henderson R.R., Fraser V.J. An evaluation of dental antibiotic prescribing practices in the United States. J. Am. Dent. Assoc. 2017;148:878–886. doi: 10.1016/j.adaj.2017.07.019.
    1. Bolfoni M.R., Pappen F.G., Pereira-Cenci T., Jacinto R.C. Antibiotic prescription for endodontic infections: A survey of Brazilian endodontists. Int. Endod. J. 2018;51:148–156. doi: 10.1111/iej.12823.
    1. Struyf T., Vandael E., Leroy R., Mertens K., Catry B. Antimicrobial prescribing by Belgian dentists in ambulatory care, from 2010 to 2016. Int. Dent. J. 2019;69:480–487. doi: 10.1111/idj.12512.
    1. Bacharier L.B., Guilbert T.W., Mauger D.T., Boehmer S., Beigelman A., Fitzpatrick A.M., Jackson D.J., Baxi S.N., Benson M., Burnham C.A.D., et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: A randomized clinical trial. JAMA J. Am. Med. Assoc. 2015;314:2034–2044. doi: 10.1001/jama.2015.13896.
    1. Salman S., Rogerson S.J., Kose K., Griffin S., Gomorai S., Baiwog F., Winmai J., Kandai J., Karunajeewa H.A., O’Halloran S.J., et al. Pharmacokinetic properties of azithromycin in pregnancy. Antimicrob. Agents Chemother. 2010;54:360–366. doi: 10.1128/AAC.00771-09.
    1. Bizjak E.D., Haug M.T., Schilz R.J., Sarodia B.D., Dresing J.M. Intravenous azithromycin-induced ototoxicity. Pharmacotherapy. 1999;19:245–248. doi: 10.1592/phco.19.3.245.30930.
    1. Serisier D.J. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir. Med. 2013;1:262–274. doi: 10.1016/S2213-2600(13)70038-9.
    1. Zhang M., Xie M., Li S., Gao Y., Xue S., Huang H., Chen K., Liu F., Chen L. Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin. Cardiovasc. Toxicol. 2017;17:434–440. doi: 10.1007/s12012-017-9401-7.
    1. Choi Y., Lim H.S., Chung D., Choi J.G., Yoon D. Risk evaluation of azithromycin-induced QT prolongation in real-world practice. Biomed Res. Int. 2018;2018:1574806. doi: 10.1155/2018/1574806.
    1. Retallack H., Di Lullo E., Arias C., Knopp K.A., Laurie M.T., Sandoval-Espinosa C., Leon W.R.M., Krencik R., Ullian E.M., Spatazza J., et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc. Natl. Acad. Sci. USA. 2016;113:14408–14413. doi: 10.1073/pnas.1618029113.
    1. Madrid P.B., Panchal R.G., Warren T.K., Shurtleff A.C., Endsley A.N., Green C.E., Kolokoltsov A., Davey R., Manger I.D., Gilfillan L., et al. Evaluation of ebola virus inhibitors for drug repurposing. ACS Infect. Dis. 2015;1:317–326. doi: 10.1021/acsinfecdis.5b00030.
    1. Bosseboeuf E., Aubry M., Nhan T., de Pina J.J., Rolain J.M., Raoult D., Musso D. Azithromycin inhibits the replication of zika virus. J. Antivir. Antiretrovir. 2018;10:6–11. doi: 10.4172/1948-5964.1000173.
    1. Gautret P., Lagier J.-C., Parola P., Hoang V.T., Meddeb L., Mailhe M., Doudier B., Courjon J., Giordanengo V., Vieira V.E., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents. 2020 doi: 10.1016/j.ijantimicag.2020.105949.
    1. Molina J.M., Delaugerre C., Goff J.L., Mela-Lima B., Ponscarme D., Goldwirt L., de Castro N. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med. Mal. Infect. 2020 doi: 10.1016/j.medmal.2020.03.006.
    1. Shoaei P., Shojaei H., Jalali M., Khorvash F., Hosseini S.M., Ataei B., Vakili B., Ebrahimi F., Tavakoli H., Esfandiari Z., et al. Clostridium difficile isolated from faecal samples in patients with ulcerative colitis. BMC Infect. Dis. 2019;19:361. doi: 10.1186/s12879-019-3965-8.
    1. Brito-Zerón P., Sisó-Almirall A., Bové A., Kostov B.A., Ramos-Casals M. Primary Sjögren syndrome: An update on current pharmacotherapy options and future directions. Expert Opin. Pharmacother. 2013;14:279–289. doi: 10.1517/14656566.2013.767333.
    1. Azzi L., Cerati M., Lombardo M., Pellilli M., Croveri F., Maurino V., Tagliabue A., Tettamanti L., Olszewska M. Chronic ulcerative stomatitis: A comprehensive review and proposal for diagnostic criteria. Oral Dis. 2019;25:1465–1491. doi: 10.1111/odi.13001.
    1. Jia L., Wang J., Wu T., Wu J., Ling J., Cheng B. In vitro and in vivo antitumor effects of chloroquine on oral squamous cell carcinoma. Mol. Med. Rep. 2017;16:5779–5786. doi: 10.3892/mmr.2017.7342.
    1. Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P., Liu X., Zhao L., Dong E., Song C., et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa237.
    1. Liu J., Cao R., Xu M., Wang X., Zhang H., Hu H., Li Y., Hu Z., Zhong W., Wang M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:1–4. doi: 10.1038/s41421-019-0132-8.
    1. Tett S., Cutler D., Day R., Brown K. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br. J. Clin. Pharmacol. 1989;27:771–779. doi: 10.1111/j.1365-2125.1989.tb03439.x.
    1. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.
    1. Savarino A., Boelaert J.R., Cassone A., Majori G., Cauda R. Effects of chloroquine on viral infections: An old drug against today’s diseases? Lancet Infect. Dis. 2003;3:722–727. doi: 10.1016/S1473-3099(03)00806-5.
    1. Golden E.B., Cho H.Y., Hofman F.M., Louie S.G., Schönthal A.H., Chen T.C. Quinoline-based antimalarial drugs: A novel class of autophagy inhibitors. Neurosurg. Focus. 2015;38:E12. doi: 10.3171/2014.12.FOCUS14748.
    1. Ponticelli C., Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE) Expert Opin. Drug Saf. 2017;16:411–419. doi: 10.1080/14740338.2017.1269168.
    1. Horta-Baas G. Chloroquine-induced oral mucosal hyperpigmentation and nail dyschromia. Reumatol. Clin. 2018;14:177–178. doi: 10.1016/j.reuma.2017.06.003.
    1. Moraes P.C., Noce C.W., Thomaz L.A., Cintra M.L., Correa M.E. Pigmented lichenoid drug eruption secondary to chloroquine therapy: An unusual presentation in lower lip. Minerva Stomatol. 2011;60:327–332.
    1. Sodhi M E.M. Safety of ibuprofen in patients with COVID-19; causal or confounded? Chest. 2020 doi: 10.1016/j.chest.2020.03.040.
    1. WHO WHO Clarifies Guidance on Ibuprofen, Says There’s No Evidence It Can Worsen COVID-19. [(accessed on 27 April 2020)]. Available online: .
    1. NICE COVID-19 Rapid Evidence Summary: Acute Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for People with or at Risk of COVID-19. [(accessed on 27 April 2020)]. Available online: .
    1. NHS England Acute Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in People with or at Risk of COVID-19 (RPS2001) [(accessed on 27 April 2020)]. Available online: .
    1. Kotfis K., Skonieczna-Żydecka K. COVID-19: Gastrointestinal symptoms and potential sources of 2019-nCoV transmission. Anaesthesiol. Intensive Ther. 2020;52 doi: 10.5114/ait.2020.93867.
    1. To K.K.-W., Tsang O.T.-Y., Chik-Yan Yip C., Chan K.-H., Wu T.-C., Chan J.M.C., Leung W.-S., Chik T.S.-H., Choi C.Y.-C., Kandamby D.H., et al. Consistent detection of 2019 novel coronavirus in saliva. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa149.
    1. To K.K., Lu L., Yip C.C., Poon R.W., Fung A.M., Cheng A., Lui D.H., Ho D.T., Hung I.F., Chan K.H., et al. Additional molecular testing of saliva specimens improves the detection of respiratory viruses. Emerg. Microbes Infect. 2017;6:1–7. doi: 10.1038/emi.2017.35.
    1. Yan J., Grantham M., Pantelic J., De Mesquita P.J.B., Albert B., Liu F., Ehrman S., Milton D.K. Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community. Proc. Natl. Acad. Sci. USA. 2018;115:1081–1086. doi: 10.1073/pnas.1716561115.
    1. Dar-Odeh N.S., Al-Kayed M.A. Variations of some salivary antimicrobial factors in different disease states: A review. Saudi Dent. J. 2002;14:99–104.
    1. Khurshid Z., Asiri F.Y.I., Al Wadaani H. Human saliva: Non-invasive fluid for detecting novel coronavirus (2019-nCoV) Int. J. Environ. Res. Public Health. 2020;17:2225. doi: 10.3390/ijerph17072225.
    1. Baboor A.S., Alnazzawi A.A., Abu-Hammad O.A., Dar-Odeh N.S. Unconventional materials and substances used in water pipe (narghile) by smokers in central western region, Saudi Arabia. Saudi Med. J. 2014;35:890–893.
    1. Giacomelli A., Pezzati L., Conti F., Bernacchia D., Siano M., Oreni L., Rusconi S., Gervasoni C., Ridolfo A.L., Rizzardini G., et al. Self-reported olfactory and taste disorders in in patients with severe acute respiratory coronavirus 2 infection: A cross-sectional study. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa330.
    1. Xu H., Zhong L., Deng J., Peng J., Dan H., Zeng X., Li T., Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci. 2020;12:1–5. doi: 10.1038/s41368-020-0074-x.
    1. Liu Z S.C. Conjunctiva is not a preferred gateway of entry for SARS-CoV-2 to infect respiratory tract. J. Med. Virol. 2020 doi: 10.1002/jmv.25859.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner